<Back to Therapeutic Areas

<Back to Menu



GSK identifies and funds innovative, high-quality, independent third-party educational initiatives that are designed to close healthcare professional (HCP) educational, quality, and performance gaps to improve patient health and quality of life. GSK provides financial support for independent medical education (IME) for HCPs, including certified continuing medical education (CME, CE), with a grant.

Educational providers are fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, speakers, and educational materials) independent from GSK control, influence, and involvement.

These initiatives offer opportunities for continual learning regarding educational topics and are free for learners to access. For more information about any of these initiatives, please click the link to be directed to the educational provider's website. All questions about these activities should be directed to the educational provider listed for each activity, not to GSK, as these are not GSK initiatives.

Severe Eosinophilic Asthma

Eosinophilic Asthma Emergence of Biologics

Expiration Date: September 29, 2022

Educational Provider: Vindico Medical Education, LLC

Hypereosinophilic Syndrome

D is for Diagnosis Rare Disorders Respiratory

Expiration Date: November 30, 2022

Educational Provider: Physicians’ Education Resource, LLC

HES An Exploration of Targeted Therapy to Improve Outcomes

Expiration Date: August 30, 2022

Educational Provider: Medical Learning Institute Inc

GSK Medical will be attending the following key congresses. Please visit us at our scientific booth or view our scientific information.

Meet Us

AAAAI | Feb 25-28, 2022 | Phoenix, AZ

ATS | May 13-18, 2022 | San Francisco, CA

AAOA | Sep 9-11, 2022 | Philadelphia, PA

AAO-HNSF | Sep 10-14, 2022 | Philadelphia, PA

AAFP | Sep 20-24, 2022 | Washington, DC

CHEST | Oct 16-19, 2022 | Nashville, TN

ACAAI | Nov 10-14, 2022 | Louisville, KY

View our ongoing, innovative research with respiratory diseases.

ASTHMA Phase I Phase II Phase III

Placebo-Controlled Efficacy and Safety Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype


A Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype


A Study of GSK3511294 Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype


Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

COPD Phase I Phase II Phase III

MATINEE: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level


Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics


View information about our respiratory portfolio of products including prescribing information, and material safety sheets.

Please see below for disease state videos, and webinars related to respiratory illnesses.


Chronic Rhinosinusitis and Comorbid Conditions: Update on Etiology and Treatment (43:25)

Chronic Rhinosinusitis, Nasal Polyps and Asthma: The Unified Airway (50:20)

Revealing Key Pathophysiology to Guide Future Management of CRS/CRSwNP (53:25)


Role of LAMAs in Asthma With Dr. Spahn (6:12)

The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease (50:00)

Asthma Ascent Escape Room Game
(An Interactive Game)

Clinical Profiles in Severe Eosinophilic Asthma (60:58)


COPD Introduction With Dr. Corbridge (6:50)

Spirometry With Dr. Corbridge (5:23)

Exacerbations With Dr. Mannino (5:32)

Exacerbation Case Study With Dr. Mannino (2:29)

Dyspnea Overview With Dr. Soler (2:45)

Dyspnea Treatment With Dr. Soler (2:33)

Dyspnea Case Study With Dr. Lettieri (4:40)

Treatable Traits With Dr. Corbridge (13:53)


EGPA: Pathogenesis, Diagnosis, and Management With Dr. Wechsler (28:06)

EGPA Mechanism of Disease (3:54)


Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders (40:56)

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease (19:53)

HES Mechanism of Disease (6:24)

GSK Respiratory Medical Team attends several key medical congresses. You can access presentations, posters, and symposia material below.

ATS 2022

May 13-18, 2022 | San Francisco, CA

AAAAI 2022

Feb 25–28, 2022 | Phoenix, AZ

ACAAI 2021

 Nov 4-8, 2021 | New Orleans, LA

CHEST 2021

Oct 17-20, 2021 | Orlando, FL | Virtual

AAOA 2021

Oct 16-21, 2021 | Virtual


Oct 3-6, 2021 | Los Angeles, CA

ARS 2021

Oct 1-2, 2021 | Los Angeles, CA

AAFP 2021

Sep 28-Oct 2, 2021 | Virtual

Please see below for disease state audio podcasts related to respiratory illnesses.

Uncontrolled Asthma: Unmet Needs With Dr. Ditto (21:44)

Uncontrolled Asthma: Putting Guidelines into Practice With Dr. Ditto (19:18)

Uncontrolled Asthma: Unmet Need With Drs. Soler and Hannania (12:30)

Uncontrolled Asthma: Practical Considerations for Primary Care With Ditto (22:03)

A Look at Diagnostic Challenges for severe Asthma (11:29)

Obstacles of diagnosing severe and/or uncontrolled asthma (reachmd.com)

Evaluating Eosinophilic Disorders: EGPA & HES (13:59)

How to better distinguish between EGPA and HES. (reachmd.com)